Welcome to our dedicated page for Collplant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CollPlant Biotechnologies Ltd (NASDAQ: CLGN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. CollPlant files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These documents include press releases on financial results, product development updates, distribution agreements, corporate governance matters and interim financial statements.
Through its Form 6-K submissions, CollPlant furnishes materials such as quarterly financial results, condensed consolidated interim financial statements, operating and financial reviews, and detailed press releases on topics like expansion of rhCollagen distribution capabilities in North America, positive non-clinical data for its photocurable dermal and soft tissue filler, and distribution expansion for its Vergenix STR tendon-repair product in Europe. Filings also cover announcements related to scientific collaborations, including studies involving its Collink.3D rhCollagen-based bioink and Mayo Clinic’s fully humanized 3D bioprinted skin model, as well as notices of shareholder meetings and proxy materials.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand financial performance, progress in regenerative and aesthetic medicine programs, and material agreements such as CollPlant’s development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company. Real-time updates from EDGAR ensure that new 6-K and 20-F reports are available promptly.
Users can review CollPlant’s historical and current filings to analyze trends in its rhCollagen-based business, monitor disclosures about collaborations and product pipelines, and better understand the regulatory context of its 3D bioprinting, tissue repair and medical aesthetics activities.
CollPlant Biotechnologies Ltd. is registering up to 3,296,000 ordinary shares for resale by selling shareholders, representing shares issuable upon exercise of warrants issued in connection with its February 2026 financing. The prospectus states the company will not receive proceeds from these resales; however, it may receive approximately $4.15 million if the warrants are exercised for cash in full.
The filing discloses 14,415,128 ordinary shares outstanding as of March 17, 2026, lists plan of distribution options for selling shareholders, and provides customary registration and risk disclosures.
CollPlant Biotechnologies reported 2025 GAAP revenue of $2.4 million, up from $515,000 in 2024, mainly from a $2 million AbbVie milestone tied to its dermal filler program. GAAP gross profit was $1.5 million versus a gross loss a year earlier.
GAAP operating expenses fell to $13.0 million from $16.1 million following a cost-reduction plan that cut the workforce by about 25%. GAAP net loss narrowed to $11.5 million, or $0.94 per share, from $16.6 million, while non-GAAP net loss was $10.2 million.
Cash and cash equivalents were $5.6 million as of December 31, 2025, with $9.4 million used in operating activities. The company highlighted progress in regenerative breast implant preclinical studies, launch of its BioFlex 3D bioprinting kit, expansion of North American distribution, and new patents in the U.S., South Korea, and Japan.
CollPlant Biotechnologies files its annual Form 20-F as a regenerative and aesthetic medicine company built around plant-derived recombinant human collagen (rhCollagen) for medical aesthetics and 3D bioprinting.
The company reported a total comprehensive loss of $11.5 million in 2025 and an accumulated deficit of $124.8 million, with $5.6 million in cash and cash equivalents as of December 31, 2025. Management and the independent auditor note substantial doubt about CollPlant’s ability to continue as a going concern due to projected negative operating cash flows and limited liquidity.
CollPlant highlights its global development and commercialization agreement with AbbVie for dermal and soft tissue fillers, under which it has received milestone payments of $14 million in 2021, $10 million in 2023, and $2 million in 2025, while stressing there is no assurance of future payments. The report details extensive risk factors, including funding needs, manufacturing scale-up challenges, regulatory uncertainty for its novel plant-based collagen platform, dependence on strategic partners, and restrictions tied to historical R&D grants from the Israel Innovation Authority.
CollPlant Biotechnologies Ltd. received a Nasdaq notice on March 23, 2026 that it is not in compliance with Nasdaq Listing Rule 5550(a)(2) because its ordinary share closing bid price has been below $1.00 per share for the last 30 consecutive business days.
The company has been given a 180-day grace period, until September 21, 2026, to regain compliance by having its closing bid at or above $1.00 for at least 10 consecutive business days. If it still does not meet the minimum bid price by that date, it may qualify for a second 180-day period if it meets other Nasdaq Capital Market initial listing standards and notifies Nasdaq of its intention to cure the deficiency, including potentially effecting a reverse share split. During this time, CollPlant’s ordinary shares remain listed and trading on the Nasdaq Capital Market while the company monitors its share price and evaluates options.
CollPlant Biotechnologies Ltd director and Chief Executive Officer Tal Yehiel filed an initial ownership report. The filing lists direct holdings of options to purchase Ordinary Shares, including grants exercisable at $4.0200 and $6.3900 per share with expirations between 2028 and 2032, covering 75,000, 37,800, 81,266 and 100,000 underlying shares. Yehiel also reports 31,137 Ordinary Shares and 80,000 restricted share units, of which 25,000 are vested and 55,000 are scheduled to vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service. Certain awards are held through a trustee to qualify for Israeli Section 102 tax benefits.
CollPlant Biotechnologies Ltd director Alisa Lask reports existing equity awards, including options and restricted share units. She holds options to purchase 47,000 Ordinary Shares at an exercise price of $6.39 per share, expiring on May 2, 2032, all held directly.
The Form 3 also reports 10,000 restricted share units held directly. According to the footnotes, 3,125 of these units are vested and 6,875 will vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service. Of the options, 44,062 are already vested and 2,938 are scheduled to vest on May 2, 2026.
CollPlant Biotechnologies Ltd director Penn Elan has filed an initial Form 3 disclosing equity interests in the company. The filing reports options to purchase 10,000 ordinary shares at $4.02 expiring in 2028, 8,000 options at $6.39 expiring in 2030, and 24,000 options at $6.39 expiring in 2032, all held directly.
Elan also holds 7,500 restricted share units, of which 625 are already vested. The remaining 6,875 units vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, contingent on continued service. Most of the option grants are already fully vested or largely vested under the disclosed schedule.
CollPlant Biotechnologies director Avraham Havron has filed an initial statement of beneficial ownership, detailing his equity-based awards in the company. The filing reports options over 4,000 ordinary shares at an exercise price of $4.02 per share, expiring on January 14, 2028, which are fully vested and exercisable. It also reports options over 8,000 ordinary shares at $6.39 per share expiring on August 27, 2030, and options over 24,000 ordinary shares at $6.39 per share expiring on May 2, 2032, of which 22,500 are currently vested and the remaining 1,500 vest on May 2, 2026 subject to continued service. In addition, he holds 10,000 restricted share units, with 3,125 already vested and 6,875 scheduled to vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, contingent on ongoing service.
CollPlant Biotechnologies Ltd executive Bagley Bowman, VP Commercial North America, filed an initial ownership report showing 25,000 restricted share units. These RSUs vest over four years: 25% on January 1, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter.
CollPlant Biotechnologies Ltd VP Legal Abelis Bar Berta filed an initial ownership report showing equity awards tied to company performance and continued service. The filing lists options to purchase 20,000 ordinary shares at an exercise price of $7.50 expiring on March 28, 2033, with 13,750 options already vested and 6,250 vesting in five equal quarterly installments from March 28, 2026 through March 28, 2027. It also reports 13,000 restricted share units, of which 5,686 are vested and 7,314 vest in nine equal quarterly installments between June 8, 2026 and June 8, 2028, plus a separate grant of 40,000 restricted share units vesting over three years, with 33% vesting on November 25, 2026 and the remaining 67% in eight equal quarterly installments thereafter.